NCT05822557

Brief Summary

The primary aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life. Secondary aims are to assess ease of use, liking, compliance, gastrointestinal tolerance, nutrient intake, anthropometric changes and safety.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable cancer

Timeline
Completed

Started Apr 2023

Shorter than P25 for not_applicable cancer

Geographic Reach
1 country

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 12, 2022

Completed
12 months until next milestone

Study Start

First participant enrolled

April 1, 2023

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 20, 2023

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 25, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 25, 2024

Completed
Last Updated

February 26, 2025

Status Verified

February 1, 2025

Enrollment Period

10 months

First QC Date

April 12, 2022

Last Update Submit

February 24, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Health and feeding related quality of life

    At baseline, and at the mid-point and end of the intervention period, health and feeding related quality of life will be assessed by the FACT-EQ questionnaire.

    Baseline to end of intervention (Day 35)

Secondary Outcomes (7)

  • Ease of administration

    Baseline to end of intervention (Day 35)

  • Liking of feeding method

    Baseline to end of intervention (Day 35)

  • Gastrointestinal tolerance

    Baseline to end of intervention (Day 35)

  • Compliance

    Baseline to end of intervention (Day 35)

  • Nutrient intake

    Baseline to end of intervention (Day 35)

  • +2 more secondary outcomes

Study Arms (1)

Bolus Pouch Feed

EXPERIMENTAL

A 250 ml feeding pouch containing 400 kcal.

Other: Bolus Pouch Feed

Interventions

Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management

Bolus Pouch Feed

Eligibility Criteria

Age16 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • ≥16 years of age
  • Using or requiring an enteral tube feed as part of nutritional management plan
  • Using or about to use bolus tube feeding methods at least once daily
  • Expected to receive at least 400 kcal/day from the intervention feed
  • Written or electronic informed consent from patient, or verbally given consent countersigned by a witness for those physically unable to sign.

You may not qualify if:

  • Parenteral nutrition contributing more than 70% of total energy requirements
  • Patients with major hepatic dysfunction (i.e., decompensated liver disease)
  • Patients with major renal dysfunction \[i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)\]
  • Patients receiving inpatient care
  • Participation in other clinical intervention studies within 2 weeks of this study
  • Adults lacking mental capacity to consent
  • Allergy to any study product ingredients
  • Investigator concern regarding ability or willingness of patient to comply with the study requirements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

University Hospitals Sussex NHS Foundation Trust

Brighton, United Kingdom

Location

Cambridge University Hospitals NHS Foundation Trust

Cambridge, United Kingdom

Location

University Hospitals Coventry and Warwickshire NHS Trust

Coventry, United Kingdom

Location

County Durham and Darlington NHS Foundation Trust

Darlington, United Kingdom

Location

NHS Tayside

Dundee, United Kingdom

Location

Royal Surrey NHS Foundation Trust

Guildford, United Kingdom

Location

Betsi Cadwaladr University Health Board

Holywell, United Kingdom

Location

Calderdale & Huddersfield NHS Foundation Trust

Huddersfield, United Kingdom

Location

Leicestershire Partnership NHS Trust

Leicester, United Kingdom

Location

North East London NHS Foundation Trust

London, United Kingdom

Location

Northumbria Healthcare NHS Foundation Trust

Newcastle upon Tyne, United Kingdom

Location

Nottingham University Hospitals NHS Trust

Nottingham, United Kingdom

Location

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, United Kingdom

Location

Southern Health NHS Foundation Trust

Southampton, United Kingdom

Location

South Warwickshire NHS Foundation Trust

Warwick, United Kingdom

Location

MeSH Terms

Conditions

NeoplasmsNervous System DiseasesStroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Rebecca Stratton, PhD

    Nutricia UK Ltd

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: This is a prospective, longitudinal, 28-day intervention study with a 7-day baseline period.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 12, 2022

First Posted

April 20, 2023

Study Start

April 1, 2023

Primary Completion

January 25, 2024

Study Completion

January 25, 2024

Last Updated

February 26, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations